The Risk of Developing Second Primary Malignancies Among Colorectal Cancer Patients

Songtao Du

Harbin Medical University

Yayun Li

Central South University

Huiyan Sun

Central South University

Furong Zeng (✉ zengflorachn@hotmail.com)

Xiangya Hospital Central South University <https://orcid.org/0000-0001-6621-8131>

Guangtong Deng

Central South University

Bomiao Zhang

Harbin Medical University

Binbin Cui

Harbin Medical University

Research Article

Keywords: colorectal cancer, second primary malignancies, standardized incidence rates, lag period

Posted Date: February 10th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1274510/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background: The increasing number of young colorectal cancer (CRC) survivors has led to ongoing concerns about the risk of secondary primary malignancies (SPMs). Here, we intended to comprehensively explore the pooled standardized incidence rates (SIRs) for total and site-specific SPMs in CRC survivors with different restriction to lag period.

Methods: Pubmed, Embase, Cochrane Library, and Web of science databases were searched to identify any studies reporting the SIRs of SPM following CRC until August 2021. Total and site-specific SIRs with different restriction to lag period were pooled using fixed/random effect models.

Results: A total of 42 full-text publications with more than 1, 524, 236 CRC survivors and 166, 210 SPM patients were included in the meta-analysis. Pooled data showed an increased SIRs for all SPMs in CRC survivors with different restriction to lag period (no restriction to lag period, SIR = 1.15, 95%CI = [1.08-1.23]; 1-year lag, 1.16 [1.10-1.23]; 5-year lag, 1.18 [1.09-1.28]; 10-year lag, 1.24 [1.11-1.39]). The conclusions were consistent for neoplasms of colorectum, corpus uteri, and small intestine with different restriction to lag period. However, limited evidence was presented for associations between CRC survivors and SPM for prostate, breast (female), ovarian, stomach, urinary bladder, kidney, thyroid, bone and soft-tissue.

Conclusion: CRC survivors are associated with an increased risk of SPMs, especially neoplasms of colorectum, corpus uteri, and small intestine. Our finding will provide the reference for patient counseling, second prevention and guidelines-making.

1. Introduction

Colorectal cancer (CRC) is the third most common cancer, with an estimated 1.9 million new cases globally in 2020, accounting for 10.2% of all new cases and 935,000 related deaths.^{1,2} The combination of curative resection and adjuvant chemotherapy has become the standard therapeutic method and has achieved a significant improvement in the overall prognosis of colorectal cancer.³⁻⁵ However, the increasing number of young colorectal cancer (CRC) survivors brought some worries about the risk of second primary malignancies (SPM),⁶ which is detrimental to the prognosis of CRC survivors.

Increasing studies have served to define the risk of SPM in CRC survivors. For example, Yang et al.⁷ reported that CRC survivors were at increased risk of total SPMs and second primary CRC, while Tanaka et al.⁸ demonstrated that the SIRs of total SPMs and CRC cancer were not statistically significant in CRC survivors. Moreover, Ringland et al.⁹ noted that the risk of second primary CRC was higher than in the general population in analysis with no restriction for latency time, while the risk was the same when restricted to studies with a lag time of 5 or 10 years. These findings suggested that it still needs to clarify the pooled SIRs for total and site-specific SPM in CRC survivors, especially with different restriction to lag period.

Here, we sought to characterize the pooled SIRs for total and site-specific SPM with restriction for different lag time in CRC survivors. To the best of our knowledge, this is the first meta-analysis showing confirmatory evidence of the increased risk of SPM in CRC survivors, especially neoplasms of colorectum, corpus uteri, and small intestine. Our finding will provide the reference for patient counseling, second prevention and guidelines-making.

2. Methods

This systematic review was conducted following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guideline, and the systematic review protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO, www.crd.york.ac.uk/prospero/) on August 2021 (CRD42021276185).

2.1 Literature search

A comprehensive systematic literature search was carried out using Pubmed, Embase, and Cochrane library and Web of Science databases to retrieve any studies that investigated the SIRs of SPM in CRC survivors from inception to August 2021. The detailed search strategies are in **Table S1**. References of eligible articles were also assessed for relevant studies.

2.2 Inclusion and exclusion criteria

For the purpose of our meta-analysis, all the studies were screened based on the following inclusion criteria: (1) CRC survivors; (2) second (subsequent or metachronous, not synchronous) primary malignancies; (3) Accessible SIR and its 95% confidence interval (CI). Exclusion criteria were as follows: (1) non-CRC patients; (2) studies with smaller sample size from the same authors or hospitals; and (3) patients or studies did not fulfill the inclusion criteria.

2.3 Data extraction and quality assessment

Three reviewers (SD, FZ, and HS) summarized the eligible studies and resolved the divisions of opinion by consensus assessment. Study characteristics (first author, publication year, study population, region, gender, and mean age) and relevant data of patient characteristics (site of the second primary tumor, mean age, sex, follow-up period, SIR, 95% confidence interval, sample size, number of incidents, observed and expected patients' number, latency time) were extracted. When SIR and its 95%CI were not reported, they were calculated based on Poisson distribution using the observed and expected incidents. Standard to identify the possible bias risk, or research rationality, in the individual studies was assessed using the Newcastle-Ottawa Scales. Studies with stars more than six were regarded as high-quality.

2.4 Statistical analysis

STATA 16.0 (Stata Corporation, College Station, TX, USA) software was used for all the analyses. The potential heterogeneity was explored by using the Cochran's Q test and I^2 test statistics. The p-value < 0.1 or I^2 > 50% indicates significant heterogeneity. The random-effect model was preferentially performed for all the analyses because of the inherent clinical heterogeneity among studies. Fixed-effect model was used to evaluate the consistency of the conclusions. Subgroup analyses stratified by sites of SPM and restriction on different lag time were performed to assess the stability of the conclusions. P-value less than 0.05 was considered statistically significant.

3. Results

3.1 Literature search and studies characteristics

A total of 15,052 unique publications were retrieved by our literature search. After titles and abstracts screening, 189 articles remained for additional full-text examination (Figure 1). It is worth mentioning that 38 independent studies were eligible based on our selection criteria derived from United States Surveillance, Epidemiology, and End Results (SEER) cohort, while the most representative studies covering the broadest range of years with the largest population was kept for our analysis to avoid duplication. The full-text reviews of these articles were carefully completed and the corresponding reasons are listed in Figure 1. Finally, 42 full publications (ranged from 1969 to 2021) met our eligibility criteria, with more than 1, 524, 236 CRC survivors and 166,210 SPM patients.⁷⁻⁴⁸

The main characteristics of the eligible studies are shown in Table 1. Of the 42 publications, the principal meta-analysis on the overall risk for SPMs in CRC survivors was based on 26 studies. Other 16 articles reporting the data of a single tumor contributed to the site-specific SIRs. Thirty-four original investigations were based on regional populations, and other eight studies were conducted from different hospitals or institutions. The mean period of follow-up, reported in 28 studies, ranged from 1.5 to 16.8 years. The mean latency period (the time between diagnosis of CRC and the SPMs) ranged from 1.5 to 6.0 years. Newcastle-Ottawa Scale (NOS) was performed to assess the methodological quality of eligible studies. All studies were identified as high-quality with stars above six (**Table S2**).

Table 1
Characteristics of included studies in meta-analysis of secondary malignancies among colorectal cancer survivals.

Study (reference)	Publish Date	Registry (study interval)	Country	Mean age at diagnosis, (Range or SD) years	Male: female ratio	Latency, mean or SD (years)	Mean Follow-up (years)	Study Size	No. of Second Malignancies
Schottenfeld ¹⁰	1969	Memorial Sloan KeHering Cancer Center (1949-1962)	USA	-	-	-	-	4771	190
Teppo ¹¹	1985	Finnish Cancer Registry (1953-1979)	Finland	-	0.62	-	-	21122	329
Enblad ¹²	1989	National Board of Health and Welfare the Swedish Cancer Registry (1960-1981)	Sweden	-	1.07	-	-	61769	3845
Tanaka ⁸	1991	Osaka Cancer Registry (1966-1986)	Japan	60.1	1.15	-	3.68	14235	416
Levi ¹³	1993	Vaud Cancer Registry (1974-1989)	Switzerland	-	1.08	-	-	-	153
Buiatti ¹⁴	1997	Tuscany Tumour Registry (RIT), Ragusa Cancer Registry (RTR), Cancer Registry of Romagna (RTR) (1981-1989)	Italy	68.6	-	-	2.7	5238	163
McCredie ¹⁵	1997	New South Wales Central Cancer Registry (1972-1991)	Australia	66.5	1.08	-	3.79	42509	2098
Malmer ¹⁶	2000	The nation-wide Swedish Cancer Registry (1958-1994)	Sweden	72	-	-	-	156872	224
Evans ¹⁷	2001	The Thames Cancer Registry (1961-1995)	England	-	0.93	-	-	127281	4317
Dong ¹⁸	2001	The Swedish Family Cancer Database (1958-1996)	Sweden	67.6	1.14	-	2.68	67899	6197
Hemmiki ¹⁹	2001	The Swedish Family Cancer Database (1958-1996)	Sweden	65.55	1.17	-	-	68084	5731

Study (reference)	Publish Date	Registry (study interval)	Country	Mean age at diagnosis, (Range or SD) years	Male: female ratio	Latency, mean or SD (years)	Mean Follow-up (years)	Study Size	No. of Second Malignancies
Green ⁴²	2002	U.S. national Cancer Institute (1989-1993)	USA	63.9±11 (15–87)	1.22	1.5 (0.3-5.8)	1.5 (0.3-5.8)	3179	42
Moot ²⁰	2002	Victorian Cancer Registry (1982-1993)	Australia	66.2	-	-	7.2	13794	279
Heard ²¹	2005	South Australian Cancer Registry (1977–2001)	Australia	-	-	-	-	-	1472
Bouvier ²²	2008	A population-based cancer registry in Burgundy (1976-2002)	France	71.1 (21.0-99.6)	1.24	3.6 (0.5-22.5)	-	10801	216
Cluze ²³	2009	Cancer Registry of Ise`re, France (1989-1997)	France	69.2	1.08	-	2.9	4944	224
Noura ²⁴	2009	Osaka Cancer Registry 1991-1996	Japan	61 (33–89)	1.71	2.5	6.8	301	40
Ringland ⁹	2010	NSW Central Cancer Registry (1987-1996)	Australia	-	1.22	Median 3.7	5.1 (1.4–10.7)	29471	660
Youlden ²⁵	2011	Queensland Cancer Registry (QCR) (1982-2001)	Australia	-	1.18	5.5 (1.3-10.2)	5-25	27814	3046
Raj ²⁶	2011	California Cancer Registry (1990-2005)	USA	64.7	1.19	2.67	6	104257	1443
Tabuchi ²⁷	2012	Osaka Cancer Registry (1985-2004)	Japan	-	-	-	3.9	-	2470
Dasgupta ²⁸	2012	Queensland, Australia 1996-2005	Australia	64	1.36	3.1	4.2 (2.2–7.3)	15755	1615
Kok ²⁹	2012	Netherlands Cancer Registry (1989-2008)	Netherlands	-	-	-	-	-	-
Mulder ³⁰	2012	Rotterdam Cancer registry in the Netherlands (1995-2006)	Netherlands	70.0 (62-77)	1.02	-	3.9	10283	135
Levi ³¹	2012	Vaud Cancer Registry (1974-2008)	Switzerland	-	1.15	-	4.7	9389	136

SEER: Surveillance, Epidemiology, and End Results.

Study (reference)	Publish Date	Registry (study interval)	Country	Mean age at diagnosis, (Range or SD) years	Male: female ratio	Latency, mean or SD (years)	Mean Follow-up (years)	Study Size	No. of Second Malignancies
Tabuchi ³²	2013	Osaka Medical Center for Cancer and Cardiovascular Diseases (1985–2004)	Japan	-	-	-	5.2	2155	204
Utada ³³	2014	Nagasaki Prefecture Cancer Registry (1985-2007)	Japan	-	-	-	4.3	-	2997
Jégu ³⁴	2014	K2 France nationwide study(1984-2004)	France	64.2	-	-	0.16-18	-	2929
Coyte ³⁵	2014	Scottish Cancer Registry(2000-2004)	Scotland	69.9±11.7	1.13	-	-	7225	324
Lee ³⁶	2015	Taiwan's national Health Insurance (1996-2011)	China	67 (56–75)	1.29	4.7 (2.7–7.5)	4.03 (2.14–7.49)	98876	4259
Liang ³⁷	2015	Taiwan Cancer Registry (TCR) (1995-2005)	China	66	1.32	-	4.4	65 648	3810
Kato ³⁸	2016	Saitama Medical Center (2007-2011)	Japan	67.4±11.2	1.73	1.5 (3-61)	3.69 (1.6)	1005	126
Preyer ³⁹	2017	Tyrol and Vorarlberg Cancer Registries (1988-2005)	Austria	-	-	-	5.7 (1.4–10.3)	7138	614
Yang ⁷	2017	SEER (1973-2012)	USA	68 (14–102)	1.36	-	6.97	288390	33047
Kim ⁴⁰	2017	Republic of Korea national Health Insurance System database (2007-2012)	Korea	-	-	-	5.78	85455	2005
Chung ⁴¹	2017	Severance Hospital (2001-2009)	Korea	61.0 (45.0–74.0)	1.62	0.3 (0.8-10)	3.3 (0–30.9)	4822	
Guan ⁴³	2015	SEER (1992-2012)	USA	-	1.42	-	-	240584	27731
He ⁴⁴	2018	SEER (1973-2013)	USA	-	-	-	-		50679

SEER: Surveillance, Epidemiology, and End Results.

Study (reference)	Publish Date	Registry (study interval)	Country	Mean age at diagnosis, (Range or SD) years	Male: female ratio	Latency, mean or SD (years)	Mean Follow-up (years)	Study Size	No. of Second Malignancies
Bright ⁴⁵	2019	The Teenage and Young Adult Cancer Survivor Study England and Wales (1971-2006)	England	-	1.03	-	16.8	5805	537
Ahn ⁴⁶	2019	Support for Serious Illness (SSI) program Korean NHI claims database (2005-2015)	Korean	65.56 ±10.51	1.58	3.08 (1.87-3.44)	-	251482	498
Feller ⁴⁷	2020	Swiss cantonal cancer registries (1981-2009)	Switzerland	-	-	6.0 (2.1-10.9)	More than 5	35949	4441
Tanaka ⁴⁸	2021	Japan Clinical Oncology Group JCOG0205, JCOG0212 and JCOG0404	Japan	62 (23–75)	1.38	-	6.0 (5.0–7.2)	2824	240
SEER: Surveillance, Epidemiology, and End Results.									

3.2 Overall and site-specific SIRs of SPM in CRC survivors

On pooled analysis with data derived from 26 studies comprising 601,601 CRC survivors and 85,708 SPM patients, we found an increased risk of second malignancies with no restriction to lag period (SIR = 1.15, 95% CI = [1.08-1.23]). The result was similar when we restricted analysis with lag one (SIR = 1.16, 95% CI = [1.10-1.23]), five (SIR = 1.18, 95%CI = [1.09-1.28]) or ten (SIR = 1.24, 95%CI = [1.11-1.39]) years (Figure 2).

Twenty-two studies with no restriction for latency time reported the association between CRC survivors and second primary CRC. The random-effect model showed that CRC survivors had a higher risk of developing second CRC (SIR = 1.59, 95% CI = [1.38-1.83]). Similar results were obtained when the analysis was restricted by one, five-, and ten-years lag (one-year lag, SIR = 1.78, 95% CI = [1.52-2.08]; five-years lag, SIR = 1.45, 95% CI = [1.15-1.82]; and ten-years lag, SIR = 1.69, 95% CI = [1.12-2.54]) (Figure 3).

Fourteen studies reported the SIR of the second neoplasm of uterine corpus in CRC survivors with no restriction for latency time. The pooled data showed a higher risk of developing the malignant neoplasm of corpus uteri using the random model (SIR = 2.11, 95% CI = [1.62-2.76]). Moreover, the SIR was still similar when we calculated the derived data stratified by different lag time (one-year lag, SIR = 2.25, 95% CI = [1.60-3.16]; five-years lag, SIR = 2.75, 95%CI = [1.00-7.58]; and ten-years lag, SIR = 1.53, 95% CI = [1.23-1.91]) (Figure 4).

Pooled analysis of seven studies with no restriction to lag time showed a positive association between second malignant of the small intestine and CRC survivors (SIR = 4.00, 95% CI = [2.91-5.49]. Restriction of the analysis with different years lag presents stable results of high risk of small intestine tumor (one-year lag, SIR = 3.38, 95% CI = [3.08-3.71]; SIR = 2.35, 95% CI = [1.99-2.78]; and SIR = 2.75, 95% CI = [2.18-3.47]) (Figure 5).

We also found that CRC survivors are more likely to develop second neoplasms of prostate, breast (female), ovarian, stomach, urinary bladder, kidney, thyroid, bone and soft-tissue (Figure S1). However, the results of the above tumors failed to be consistent with the analysis stratified by different lag time (Figure S2-9). Moreover, there were no increasing association between CRC survivors and neoplasms of stomach, oral, lymphoma, pancreas, leukemia, brain, cervix, esophagus, larynx and gall bladder (Figure S1).

4. Discussion

An increasing number of young CRC survivors are confronted with the threat of developing SPM.⁶ Appropriate risk assessment for SPMs has substantial therapeutic implications for long-term patient surveillance and the reduction of morbidity. In this study, based on the 41 publications from comprehensive population databases worldwide, we carried out a meta-analysis to explore the risk of overall SPMs in CRC survivors. Our results demonstrated that CRC survivors were at increased risk of developing second tumors, especially neoplasms of colorectum, corpus uteri, and small intestine.

To our knowledge, this is the first meta-analysis to comprehensively evaluate the risk of SPMs in CRC survivors. Consistent with our findings, Keegan et al. demonstrated that SIR of overall SPMs was about 1.14 in CRC survivors.⁴⁹ However, his team, like others, mainly focused on overall SPMs risk, but ignored site-specific SIRs^{13,25}. The site-specific SIRs could precisely facilitate the management of disease surveillance in CRC survivors. In this point, our study is of great significance in the field.

Our results confirmed the positive association between SPMs and CRC history,^{50,51} and the reasons may be as follows, (1) genetic predisposition and environmental exposures;^{9,30,52,53} (2) adjuvant therapy, such as radiotherapy⁵⁴ and chemotherapy⁵⁵. Previous reports showed that the challenge of the bone marrow faced with the toxic and mutagenic effects of chemotherapy made the circulatory system vulnerable to the hematologic tumor.^{50,56} Moreover, direct radiation, radiation scatter or radiation induced genetic alterations with direct exposure might contribute to carcinogenesis due to increased reactive oxygen species and changes of gene expression.⁵⁷

Inevitably, there are several limitations related to this meta-analysis. First, significant heterogeneity existed among the analysis, while different effect models and subgroup analyses showed a unified result, which further confirmed the conclusion. Second, some SIRs and their 95% CI were estimated based on Poisson distribution using the observed and expected cases, which could cause some bias of results. Finally, mutagenic and immunosuppressive effects of chemotherapy and radiotherapy treatment could affect our results due to lack of the treatment data.

5. Conclusion

In summary, for the first time, we reported that CRC survivors are associated with an increased risk of SPMs, especially neoplasms of colorectum, corpus uteri, and small intestine. Our finding will provide the reference for patient counseling, second prevention and guidelines-making.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

The content of this manuscript has not been previously published and all authors have agreed to publish this manuscript.

Availability of data and materials

The datasets supporting the conclusions of this article are accessible upon reasonable requests from the corresponding authors.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by the National Natural Science Foundation of China (No. 82102803, 82103183), Youth Natural Science Foundation of Heilongjiang Province (JJ2018QN0724); Haiyan Fund Project of Harbin Medical University Cancer Hospital (JJMS2021-24)

Authors' contributions

Furong Zeng, Songtao Du, Bomiao Zhang, and Binbin Cui conceived and designed the study. Songtao Du and Yayun Li analyzed the data. Songtao Du and Yayun Li wrote the manuscript. Huiyan Sun and Yayun Li and Guangtong Deng revised the manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGEMENTS

None

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: a cancer journal for clinicians*. May 2021;71(3):209-249. doi:10.3322/caac.21660
2. Yoshino T, Argilés G, Oki E, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. *Annals of oncology : official journal of the European Society for Medical Oncology*. Aug 16 2021;doi:10.1016/j.annonc.2021.08.1752
3. Papamichael D, Audisio RA, Glimelius B, et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. *Annals of oncology : official journal of the European Society for Medical Oncology*. Mar 2015;26(3):463-76. doi:10.1093/annonc/mdu253
4. West NP, Hohenberger W, Weber K, Perrakis A, Finan PJ, Quirke P. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Jan 10 2010;28(2):272-8. doi:10.1200/jco.2009.24.1448
5. Seymour MT, Morton D. F0XTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. 2019:
6. El-Shami K, Oeffinger KC, Erb NL, et al. American Cancer Society Colorectal Cancer Survivorship Care Guidelines. *CA: a cancer journal for clinicians*. Nov-Dec 2015;65(6):428-55. doi:10.3322/caac.21286
7. Yang J, Li S, Lv M, et al. Risk of subsequent primary malignancies among patients with prior colorectal cancer: a population-based cohort study. *OncoTargets and therapy*. 2017;10:1535-1548. doi:10.2147/ott.S129220
8. Tanaka H, Hiyama T, Hanai A, Fujimoto I. Second primary cancers following colon and rectal cancer in Osaka, Japan. *Japanese journal of cancer research : Gann*. Dec 1991;82(12):1356-65. doi:10.1111/j.1349-7006.1991.tb01806.x
9. Ringland CL, Arkenau HT, O'Connell DL, Ward RL. Second primary colorectal cancers (SPCRCs): experiences from a large Australian Cancer Registry. *Annals of oncology : official journal of the European Society for Medical Oncology*. Jan 2010;21(1):92-7. doi:10.1093/annonc/mdp288
10. Schottenfeld D, Berg JW, Vitsky B. Incidence of multiple primary cancers. II. Index cancers arising in the stomach and lower digestive system. *Journal of the National Cancer Institute*. Jul 1969;43(1):77-86.
11. Teppo L, Pukkala E, Saxén E. Multiple cancer—an epidemiologic exercise in Finland. *Journal of the National Cancer Institute*. Aug 1985;75(2):207-17.
12. Enblad P, Adami HO, Glimelius B, Krusemo U, Pahlman L. The risk of subsequent primary malignant diseases after cancers of the colon and rectum. A nationwide cohort study. *Cancer*. May 1 1990;65(9):2091-100. doi:10.1002/1097-0142(19900501)65:9<2091::aid-cnrcr2820650934>3.0.co;2-m
13. Levi F, Randimbison L, Te VC, Rolland-Portal I, Franceschi S, La Vecchia C. Multiple primary cancers in the Vaud Cancer Registry, Switzerland, 1974-89. *British journal of cancer*. Feb 1993;67(2):391-5. doi:10.1038/bjc.1993.72
14. Buiatti E, Crocetti E, Acciai S, et al. Incidence of second primary cancers in three Italian population-based cancer registries. *European journal of cancer (Oxford, England : 1990)*. Oct 1997;33(11):1829-34. doi:10.1016/s0959-8049(97)00173-1
15. McCredie M, Macfarlane GJ, Bell J, Coates M. Second primary cancers after cancers of the colon and rectum in New South Wales, Australia, 1972-1991. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. Mar 1997;6(3):155-60.
16. Malmer B, Tavelin B, Henriksson R, Grönberg H. Primary brain tumours as second primary: a novel association between meningioma and colorectal cancer. *International journal of cancer*. Jan 1 2000;85(1):78-81. doi:10.1002/(sici)1097-0215(20000101)85:1<78::aid-ijc14>3.0.co;2-s

17. Evans HS, Møller H, Robinson D, Lewis CM, Bell CM, Hodgson SV. The risk of subsequent primary cancers after colorectal cancer in southeast England. *Gut*. May 2002;50(5):647-52. doi:10.1136/gut.50.5.647
18. Dong C, Hemminki K. Second primary neoplasms in 633,964 cancer patients in Sweden, 1958-1996. *International journal of cancer*. Jul 15 2001;93(2):155-61. doi:10.1002/ijc.1317
19. Hemminki K, Li X, Dong C. Second primary cancers after sporadic and familial colorectal cancer. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*. Jul 2001;10(7):793-8.
20. Moot AR, Polglase A, Giles GG, Garson OM, Thursfield V, Gunter D. Men with colorectal cancer are predisposed to prostate cancer. *ANZ journal of surgery*. May 2003;73(5):289-93. doi:10.1046/j.1445-2197.2003.t01-1-02621.x
21. Heard A, Roder D, Luke C. Multiple primary cancers of separate organ sites: implications for research and cancer control (Australia). *Cancer causes & control : CCC*. Jun 2005;16(5):475-81. doi:10.1007/s10552-004-8023-0
22. Bouvier AM, Latournerie M, Jooste V, Lepage C, Cottet V, Faivre J. The lifelong risk of metachronous colorectal cancer justifies long-term colonoscopic follow-up. *European journal of cancer (Oxford, England : 1990)*. Mar 2008;44(4):522-7. doi:10.1016/j.ejca.2008.01.007
23. Cluze C, Delafosse P, Seigneurin A, Colonna M. Incidence of second cancer within 5 years of diagnosis of a breast, prostate or colorectal cancer: a population-based study. *European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)*. Sep 2009;18(5):343-8. doi:10.1097/CEJ.0b013e32832abd76
24. Noura S, Ohue M, Seki Y, et al. Second primary cancer in patients with colorectal cancer after a curative resection. *Digestive surgery*. 2009;26(5):400-5. doi:10.1159/000229991
25. Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. *BMC cancer*. Feb 23 2011;11:83. doi:10.1186/1471-2407-11-83
26. Raj KP, Taylor TH, Wray C, Stamos MJ, Zell JA. Risk of second primary colorectal cancer among colorectal cancer cases: a population-based analysis. *Journal of carcinogenesis*. Mar 17 2011;10:6. doi:10.4103/1477-3163.78114
27. Tabuchi T, Ito Y, Ioka A, Miyashiro I, Tsukuma H. Incidence of metachronous second primary cancers in Osaka, Japan: update of analyses using population-based cancer registry data. *Cancer science*. Jun 2012;103(6):1111-20. doi:10.1111/j.1349-7006.2012.02254.x
28. Dasgupta P, Youlden DR, Baade PD. Multiple primary cancers among colorectal cancer survivors in Queensland, Australia, 1996-2007. *Cancer causes & control : CCC*. Aug 2012;23(8):1387-98. doi:10.1007/s10552-012-9990-1
29. Kok DE, van de Schans SA, Liu L, et al. Risk of prostate cancer among cancer survivors in the Netherlands. *Cancer epidemiology*. Apr 2013;37(2):140-5. doi:10.1016/j.canep.2012.11.004
30. Mulder SA, Kranse R, Damhuis RA, Ouwendijk RJ, Kuipers EJ, van Leerdam ME. The incidence and risk factors of metachronous colorectal cancer: an indication for follow-up. *Diseases of the colon and rectum*. May 2012;55(5):522-31. doi:10.1097/DCR.0b013e318249db00
31. Levi F, Randimbison L, Blanc-Moya R, et al. High constant incidence of second primary colorectal cancer. *International journal of cancer*. Apr 1 2013;132(7):1679-82. doi:10.1002/ijc.27780
32. Tabuchi T, Ito Y, Ioka A, Nakayama T, Miyashiro I, Tsukuma H. Tobacco smoking and the risk of subsequent primary cancer among cancer survivors: a retrospective cohort study. *Annals of oncology : official journal of the European Society for Medical Oncology*. Oct 2013;24(10):2699-2704. doi:10.1093/annonc/mdt279
33. Utada M, Ohno Y, Hori M, Soda M. Incidence of multiple primary cancers and interval between first and second primary cancers. *Cancer science*. Jul 2014;105(7):890-6. doi:10.1111/cas.12433
34. Jégu J, Colonna M, Daubisse-Marliac L, et al. The effect of patient characteristics on second primary cancer risk in France. *BMC cancer*. Feb 15 2014;14:94. doi:10.1186/1471-2407-14-94
35. Coyte A, Morrison DS, McLoone P. Second primary cancer risk - the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study. *BMC cancer*. Apr 18 2014;14:272. doi:10.1186/1471-2407-14-272
36. Lee YT, Liu CJ, Hu YW, et al. Incidence of Second Primary Malignancies Following Colorectal Cancer: A Distinct Pattern of Occurrence Between Colon and Rectal Cancers and Association of Co-Morbidity with Second Primary Malignancies in a Population-Based Cohort of 98,876 Patients in Taiwan. *Medicine*. Jul 2015;94(26):e1079. doi:10.1097/md.0000000000001079
37. Liang YH, Shao YY, Chen HM, et al. Young patients with colorectal cancer have increased risk of second primary cancers. *Japanese journal of clinical oncology*. Nov 2015;45(11):1029-35. doi:10.1093/jjco/hyv137

38. Kato T, Alonso S, Muto Y, Perucho M, Rikiyama T. Tumor size is an independent risk predictor for metachronous colorectal cancer. *Oncotarget*. Apr 5 2016;7(14):17896-904. doi:10.18632/oncotarget.7555
39. Preyer O, Concin N, Obermair A, Concin H, Ulmer H, Oberaigner W. The relative risk of second primary cancers in Austria's western states: a retrospective cohort study. *BMC cancer*. Oct 24 2017;17(1):699. doi:10.1186/s12885-017-3683-9
40. Kim HS, Choi YJ, Shin DW, et al. Secondary Primary Prostate Cancer after Colorectal Cancer: A Nationwide Population-based Cohort Study in Korea. *Journal of cancer prevention*. Dec 2017;22(4):241-247. doi:10.15430/jcp.2017.22.4.241
41. Chung JW, Chung MJ, Bang S, et al. Assessment of the Risk of Colorectal Cancer Survivors Developing a Second Primary Pancreatic Cancer. *Gut and liver*. Sep 15 2017;11(5):728-732. doi:10.5009/gnl16526
42. Green RJ, Metlay JP, Probert K, et al. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. *Annals of internal medicine*. Feb 19 2002;136(4):261-9. doi:10.7326/0003-4819-136-4-200202190-00005
43. Guan X, Jin Y, Chen Y, et al. The Incidence Characteristics of Second Primary Malignancy after Diagnosis of Primary Colon and Rectal Cancer: A Population Based Study. *PloS one*. 2015;10(11):e0143067. doi:10.1371/journal.pone.0143067
44. He X, Wu W, Ding Y, Li Y, Si J, Sun L. Excessive risk of second primary cancers in young-onset colorectal cancer survivors. *Cancer medicine*. Apr 2018;7(4):1201-1210. doi:10.1002/cam4.1437
45. Bright CJ, Reulen RC, Winter DL, et al. Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study. *The Lancet Oncology*. Apr 2019;20(4):531-545. doi:10.1016/s1470-2045(18)30903-3
46. Ahn HS, Kang TU, Swan H, et al. Incidence and Mortality Rates of Second Pancreatic Cancer Among Survivors of Digestive Cancers: A Nationwide Population-Based Study. *Pancreas*. Mar 2019;48(3):412-419. doi:10.1097/mpa.0000000000001254
47. Feller A, Matthes KL, Bordoni A, et al. The relative risk of second primary cancers in Switzerland: a population-based retrospective cohort study. *BMC Cancer*. Jan 21 2020;20(1):51. doi:10.1186/s12885-019-6452-0
48. Tanaka K, Ogawa G, Mizusawa J, et al. Second primary cancers and recurrence in patients after resection of colorectal cancer: An integrated analysis of trials by Japan Clinical Oncology Group: JCOG1702A. *Jpn J Clin Oncol*. Feb 8 2021;51(2):185-191. doi:10.1093/jjco/hyaa184
49. Keegan THM, Bleyer A, Rosenberg AS, Li Q, Goldfarb M. Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors. *JAMA Oncol*. Nov 1 2017;3(11):1554-1557. doi:10.1001/jamaoncol.2017.0465
50. Pirani M, Marcheselli R, Marcheselli L, Bari A, Federico M, Sacchi S. Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. *Annals of oncology : official journal of the European Society for Medical Oncology*. Aug 2011;22(8):1845-58. doi:10.1093/annonc/mdq697
51. Goyal A, O'Leary D, Goyal K, Patel K, Pearson D, Janakiram M. Cutaneous T-cell lymphoma is associated with increased risk of lymphoma, melanoma, lung cancer, and bladder cancer: A systematic review and meta-analysis. *Journal of the American Academy of Dermatology*. Aug 18 2020;doi:10.1016/j.jaad.2020.06.1033
52. Das A, Chak A, Cooper GS. Temporal trend in relative risk of second primary colorectal cancer. *Am J Gastroenterol*. Jun 2006;101(6):1342-7. doi:10.1111/j.1572-0241.2006.00580.x
53. Yang L, Xiong Z, Xie QK, et al. Second primary colorectal cancer after the initial primary colorectal cancer. *BMC Cancer*. Sep 27 2018;18(1):931. doi:10.1186/s12885-018-4823-6
54. Berrington de Gonzalez A, Curtis RE, Kry SF, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. *The Lancet Oncology*. Apr 2011;12(4):353-60. doi:10.1016/s1470-2045(11)70061-4
55. Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. *Nature reviews Cancer*. Dec 2005;5(12):943-55. doi:10.1038/nrc1749
56. Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. *Annals of oncology : official journal of the European Society for Medical Oncology*. Dec 2006;17(12):1749-60. doi:10.1093/annonc/mdl302
57. Oh KS, Sandler HM. CounterPoint: second malignancies after radiotherapy for prostate cancer: keeping perspective. *Urology*. Nov 2008;72(5):971-3. doi:10.1016/j.urology.2008.07.016

Figures

Figure 1

The flow chart of studies with corresponding exclusive reasons.

Follow-up interval	N	Size	Observed	Q-test	% I ²	Model		SIR	95%CI
No restriction for latency	26	601601	85708	<0.001	98.4	Random		1.15	1.08-1.23
						Fixed		1.10	1.09-1.11
Latency≥1 year	11	348842	45982	<0.001	95.9	Random		1.16	1.10-1.23
						Fixed		1.16	1.15-1.17
Latency≥5 years	9	218989	16258	<0.001	92.6	Random		1.18	1.09-1.28
						Fixed		1.13	1.11-1.15
Latency≥10 years	7	266080	7075	<0.001	94.2	Random		1.24	1.11-1.39
						Fixed		1.17	1.14-1.20
							1	1.39

Figure 2

The pooled standardized incidence rates (SIR) for overall second primary malignancies (SPM) in CRC survivors with different restriction to lag time.

Figure 3

The pooled SIR for second colorectal cancer in CRC survivors with different restriction to lag time.

Figure 4

The pooled SIR for second neoplasm of corpus uteri in CRC survivors with different restriction to lag time.

Figure 5

The pooled SIR for second neoplasm of small intestine in CRC survivors with different restriction to lag time.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [FigureS1total.tif](#)
- [FigureS2prostate.tif](#)
- [FigureS3breast.tif](#)
- [FigureS4ovary.tif](#)
- [FigureS5stomach.tif](#)
- [FigureS6bladder.tif](#)
- [FigureS7kidney.tif](#)
- [FigureS8thyroid.tif](#)
- [FigureS9Softtissue.tif](#)
- [TableS1.docx](#)

- [TableS2.docx](#)